Skip to main content
SpringerLink
Log in

Thallium-201 SPECT: the optimal prediction of response in glioma therapy

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to estimate 201Tl SPECT and CT-MRI cut-off values that lead to a validated prognostic classification for the end-point overall survival, in order to discriminate glioma patients with good and poor prognosis at an early stage during chemotherapeutic treatment.

Methods

We studied patients who underwent 201Tl SPECT and CT-MRI before and after two courses of chemotherapy. Cut-off values were retrieved from the Cox model. Patients were classified according to the computed cut-off values, creating subgroups of patients with different prognosis in terms of survival [tumour regression (TR); stable disease (SD); tumour progression (TP)]. The differences between the subgroups were assessed by Kaplan-Meier analyses. The predictive performance of the classification procedure was evaluated by a leave-one-out cross-validation method.

Results

201Tl SPECT classified 41% of the patients as SD, 25% as TR and 34% as TP. CT-MRI classified 82% of the patients as SD, and only 4% and 14% as TR and TP, respectively. Of those patients with a relatively long overall survival (i.e. ≥16 months), cross-validation estimates of 201Tl SPECT classification rates were 50% TR and 50% SD, and cross-validation estimates of CT-MRI classification rates were 7% TR, 72% SD, and 21% TP.

Conclusion

We constructed a 201Tl SPECT model that makes it possible to identify glioma patients with a good or a poor prognosis at an early stage during chemotherapeutic treatment. With this model, accurate predictions can be made with regard to the expected duration of survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J Neuro-oncol 1999;42:227–31

    Article  Google Scholar 

  2. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993;26:239–44

    PubMed  Google Scholar 

  3. Metcalfe SE, Grant R. Biopsy versus resection for malignant glioma. Cochrane Database Syst Rev 2001;(3):CD002034

  4. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49:333–43

    PubMed  Google Scholar 

  5. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47:649–52

    PubMed  Google Scholar 

  6. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585–97

    PubMed  Google Scholar 

  7. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001;19:509–18

    Google Scholar 

  8. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011–8

    PubMed  Google Scholar 

  9. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473–9

    Article  PubMed  Google Scholar 

  10. van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51:1140–5

    PubMed  Google Scholar 

  11. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572

    PubMed  Google Scholar 

  12. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80

    PubMed  Google Scholar 

  13. Perry JR, Cairncross JG. Glioma therapies: how to tell which work? J Clin Oncol 2003;21:3547–9

    Google Scholar 

  14. Perry JR, DeAngelis LM, Schold SC Jr, Burger PC, Brem H, Brown MT, et al. Challenges in the design and conduct of phase III brain tumor therapy trials. Neurology 1997;49:912–7

    PubMed  Google Scholar 

  15. Zeltzer PM, Friedman HS, Norris DG, Ragab AH. Criteria and definitions for response and relapse in children with brain tumors. Cancer 1985;56:1824–6

    Google Scholar 

  16. Brada M, Yung WK. Clinical trial end points in malignant glioma: need for effective trial design strategy. Semin Oncol 2000;27:11–9

    Google Scholar 

  17. Byrne TN. Imaging of gliomas. Semin Oncol 1994;21:162–71

    PubMed  Google Scholar 

  18. Kaplan RS. Complexities, pitfalls, and strategies for evaluating brain tumor therapies. Curr Opin Oncol 1998;10:175–8

    PubMed  Google Scholar 

  19. Cairncross JG, Pexman JHW, Rathbone MP, DelMaestro RF. Postoperative contrast enhancement in patients with brain tumor. Ann Neurol 1985;17:570–2

    Article  PubMed  Google Scholar 

  20. Forsyth PAJ, Petrov E, Mahallati H, Cairncross JG, Brasher P, MacRae ME, et al. Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas. J Clin Oncol 1997;15:2076–81

    Google Scholar 

  21. Kumar AJ, Leeds NE, Fuller GN, van Tassel P, Maor MH, Sawaya RE, et al. Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217:377–84

    PubMed  Google Scholar 

  22. Vos MJ, Uitdehaag BMJ, Barkhof F, Heimans JJ, Baayen HC, Boogerd W, et al. Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 2003;60:826–30

    PubMed  Google Scholar 

  23. Benard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 2003;33:148–62

    Article  PubMed  Google Scholar 

  24. Yamamoto Y, Nishiyama Y, Toyama Y, Kunishio K, Satoh K, Ohkawa M. 99mTc-MIBI and 201Tl SPET in the detection of recurrent brain tumours after radiation therapy. Nucl Med Commun 2002;23:1183–90

    Article  PubMed  Google Scholar 

  25. Schwartz RB, Holman BL, Polak JF, Garada BM, Schwartz MS, Folkerth R, et al. Dual-isotope single-photon emission computerized tomography scanning in patients with glioblastoma multiforme: association with patient survival and histopathological characteristics of tumor after high-dose radiotherapy. J Neurosurg 1998;89:60–8

    PubMed  Google Scholar 

  26. Schwartz RB, Carvalho PA, Alexander E III, Loeffler JS, Folkerth R, Holman BL. Radiation necrosis vs high-grade recurrent glioma: differentiation by using dual-isotope SPECT with 201TI and 99mTc-HMPAO. Am J Neuroradiol 1991;12:1187–92

    PubMed  Google Scholar 

  27. Gomez-Rio M, Martinez del Valle Torres D, Rodriguez-Fernandez A, Llamas-Elvira JM, Lozano SO, Font CR, et al. 201TI-SPECT in low-grade gliomas: diagnostic accuracy in differential diagnosis between tumour recurrence and radionecrosis. Eur J Nucl Med Mol Imaging 2004;31:1237–43

    PubMed  Google Scholar 

  28. Vos MJ, Hoekstra OS, Barkhof F, Berkhof J, Heimans JJ, van Groeningen CJ, et al. Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. J Clin Oncol 2003;21:3559–65

    Google Scholar 

  29. Roesdi MF, Postma TJ, Hoekstra OS, van Groeningen CJ, Wolbers JG, Heimans JJ. Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma. J Neurooncol 1998;40:251–5

    Article  Google Scholar 

  30. Källén K, Geijer B, Malmström P, Andersson AM, Holtas S, Ryding E, et al. Quantitative 201Tl SPET imaging in the follow-up of treatment for brain tumour: a sensitive tool for the early identification of response to chemotherapy? Nucl Med Commun 2000;21:259–67

    Article  PubMed  Google Scholar 

  31. Källén K, Burtscher IM, Holtås S, Ryding E, Rosen I. 201Thallium SPECT and 1H-MRS compared with MRI in chemotherapy monitoring of high-grade malignant astrocytomas. J Neurooncol 2000;46:173–85

    Article  Google Scholar 

  32. Vallejos V, Balaña C, Fraile M, Roussos Y, Capellades J, Cuadras P, et al. Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas. J Neurooncol 2002;59:81–90

    Article  Google Scholar 

  33. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704–10

    PubMed  Google Scholar 

  34. Tony B, Vos MJ, Berkhof J, Postma TJ, van Lingen A, Heimans JJ, et al. Interobserver variability in the semi-quantitative assessment of 201Tl SPECT in cerebral gliomas. Nucl Med Commun 2005;26:45–8

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank B.M.J. Uitdehaag for statistical assistence.

Author information

Authors and Affiliations

  1. Department of Neurology, VU University Medical Centre, PO Box 7057, 1007 MB, Amsterdam, The Netherlands

    Maaike J. Vos, Tjeerd J. Postma & Jan J. Heimans

  2. Department of Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, The Netherlands

    Johannes Berkhof & Otto S. Hoekstra

  3. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, The Netherlands

    Otto S. Hoekstra

  4. Department of Radiology, VU University Medical Centre, Amsterdam, The Netherlands

    Frederik Barkhof

Authors
  1. Maaike J. Vos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes Berkhof
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tjeerd J. Postma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Otto S. Hoekstra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frederik Barkhof
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jan J. Heimans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maaike J. Vos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vos, M.J., Berkhof, J., Postma, T.J. et al. Thallium-201 SPECT: the optimal prediction of response in glioma therapy. Eur J Nucl Med Mol Imaging 33, 222–227 (2006). https://doi.org/10.1007/s00259-005-1883-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-1883-z

Keywords

Search

Navigation